Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer

The dose-related adverse effects of MDM2‒P53 inhibitors have caused significant concern in the development of clinical safe anticancer agents. Herein we report an unprecedented homo-PROTAC strategy for more effective disruption of MDM2‒P53 interaction. The design concept is inspired by the capacity...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Shipeng, Ma, Junhui, Fang, Yuxin, Liu, Ying, Wu, Shanchao, Dong, Guoqiang, Wang, Wei, Sheng, Chunquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245912/
https://www.ncbi.nlm.nih.gov/pubmed/34221872
http://dx.doi.org/10.1016/j.apsb.2020.11.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245912/
https://www.ncbi.nlm.nih.gov/pubmed/34221872
http://dx.doi.org/10.1016/j.apsb.2020.11.022

Ejemplares similares